drug · small molecule

icosapent ethyl

Marketedupdated 5mo ago

by KD Pharma Group SA🔗 ChEMBL

Approved

community read0 votes

🐶 often sniffed alongside

top 8

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 6 investigational indications.

all catalysts(0)

nothing on the calendar yet

Trials studying icosapent ethyl

phase3FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCCrecruitingn=650
phase2A Study to Investigate the Safety and Efficacy of Efimosfermin Alfa Compared With Placebo in Adult Participants With Alcohol-related Liver Disease (ALD)recruitingn=274
phase4Long-term Study Evaluating Joint Health in People With Haemophilia A Receiving Real-world Prophylactic Treatment With Efanesoctocog Alfaactive not recruitingn=252
phase3A Clinical Trial of Bomedemstat in Participants With Polycythemia Vera (MK-3543-025)recruitingn=380
phase1A Study on IB-001 Dose Response and Tolerability in Healthy Adults and Those With Chronic Hepatitis Brecruitingn=88
phase3A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)recruitingn=876
phase2NAI Plus Standard of Care Compared With Placebo Plus Standard of Care in Critically Ill Adults With Sepsisnot yet recruitingn=50
phase3A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) and Pembrolizumab (MK-3475A) in Participants With Bladder Cancer (MK-2870-055)not yet recruitingn=400

Patent cliff

source: FDA Orange Book

first barrier falls

May 31, 2027

238 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (122)

Jun 28, 2033method-of-use (U-2701)US 10278935
Jun 28, 2033method-of-use (U-2701)US 10278935
Jun 28, 2033method-of-use (U-2702)US 10278936
Jun 28, 2033method-of-use (U-2702)US 10278936
Jun 28, 2033method-of-use (U-2703)US 10278937
Jun 28, 2033method-of-use (U-2703)US 10278937
Jun 28, 2033method-of-use (U-2704)US 10383840
Jun 28, 2033method-of-use (U-2704)US 10383840
Jun 28, 2033method-of-use (U-2743)US 10555924
Jun 28, 2033method-of-use (U-2743)US 10555924
Jun 28, 2033method-of-use (U-2744)US 10555925
Jun 28, 2033method-of-use (U-2744)US 10555925
Jun 28, 2033method-of-use (U-2756)US 10568861
Jun 28, 2033method-of-use (U-2756)US 10568861
Jun 28, 2033method-of-use (U-2762)US 10576054
Jun 28, 2033method-of-use (U-2762)US 10576054
Jun 28, 2033method-of-use (U-2841)US 10668042
Jun 28, 2033method-of-use (U-2841)US 10668042
Jun 28, 2033method-of-use (U-2960)US 10786478
Jun 28, 2033method-of-use (U-2960)US 10786478
Jun 28, 2033method-of-use (U-2962)US 10792270
Jun 28, 2033method-of-use (U-2962)US 10792270
Jun 28, 2033method-of-use (U-3053)US 10894028
Jun 28, 2033method-of-use (U-3053)US 10894028
Jun 28, 2033method-of-use (U-3126)US 11000499
Jun 28, 2033method-of-use (U-3126)US 11000499
Jun 28, 2033method-of-use (U-3221)US 11116742
Jun 28, 2033method-of-use (U-3221)US 11116742
Jun 28, 2033method-of-use (U-3358)US 11298333
Jun 28, 2033method-of-use (U-3358)US 11298333
Jun 28, 2033method-of-use (U-2841)US 11369582
Jun 28, 2033method-of-use (U-2841)US 11369582
Jun 28, 2033method-of-use (U-2696)US 9603826
Jun 28, 2033method-of-use (U-2696)US 9603826
Jun 28, 2033method-of-use (U-2697)US 9610272
Jun 28, 2033method-of-use (U-2697)US 9610272
Jun 28, 2033method-of-use (U-2698)US 9623001
Jun 28, 2033method-of-use (U-2698)US 9623001
Jun 28, 2033method-of-use (U-2697)US 9693984
Jun 28, 2033method-of-use (U-2697)US 9693984
Jun 28, 2033method-of-use (U-2696)US 9693985
Jun 28, 2033method-of-use (U-2696)US 9693985
Jun 28, 2033method-of-use (U-2698)US 9693986
Jun 28, 2033method-of-use (U-2698)US 9693986
Jun 28, 2033method-of-use (U-2699)US 9918954
Jun 28, 2033method-of-use (U-2699)US 9918954
Jun 15, 2030method-of-use (U-2688)US 108427683.7y
Jun 15, 2030method-of-use (U-2688)US 108427683.7y
Jun 15, 2030method-of-use (U-2688)US 84100863.7y
Jun 15, 2030method-of-use (U-2688)US 84100863.7y
Jun 15, 2030method-of-use (U-2690)US 84554723.7y
Jun 15, 2030method-of-use (U-2694)US 86692453.7y
Jun 15, 2030method-of-use (U-2694)US 86692453.7y
Jun 15, 2030method-of-use (U-2690)US 87100413.7y
Jun 15, 2030method-of-use (U-2690)US 87100413.7y
Apr 29, 2030method-of-use (U-2690)US 100105173.6y
Apr 29, 2030method-of-use (U-2690)US 100105173.6y
Apr 29, 2030method-of-use (U-2700)US 102652873.6y
Apr 29, 2030method-of-use (U-2700)US 102652873.6y
Apr 29, 2030method-of-use (U-2961)US 107922673.6y
Apr 29, 2030method-of-use (U-2961)US 107922673.6y
Apr 29, 2030method-of-use (U-2997)US 108427663.6y
Apr 29, 2030method-of-use (U-2997)US 108427663.6y
Apr 29, 2030method-of-use (U-3052)US 108816323.6y
Apr 29, 2030method-of-use (U-3052)US 108816323.6y
Apr 29, 2030method-of-use (U-3209)US 111034773.6y
Apr 29, 2030method-of-use (U-3209)US 111034773.6y
Apr 29, 2030method-of-use (U-3240)US 111545263.6y
Apr 29, 2030method-of-use (U-3240)US 111545263.6y
Apr 29, 2030method-of-use (U-3292)US 112135043.6y
Apr 29, 2030method-of-use (U-3292)US 112135043.6y
Apr 29, 2030method-of-use (U-3669)US 117175043.6y
Apr 29, 2030method-of-use (U-3669)US 117175043.6y
Apr 29, 2030formulationUS 82985543.6y
Apr 29, 2030formulationUS 82985543.6y
Apr 29, 2030method-of-use (U-1287)US 84450033.6y
Apr 29, 2030method-of-use (U-1287)US 84450033.6y
Apr 29, 2030method-of-use (U-1287)US 84450133.6y
Apr 29, 2030method-of-use (U-1287)US 84450133.6y
Apr 29, 2030method-of-use (U-2689)US 84549943.6y
Apr 29, 2030method-of-use (U-2689)US 84549943.6y
Apr 29, 2030method-of-use (U-1287)US 85012253.6y
Apr 29, 2030method-of-use (U-1287)US 85012253.6y
Apr 29, 2030method-of-use (U-1287)US 85515213.6y
Apr 29, 2030method-of-use (U-1287)US 85515213.6y
Apr 29, 2030method-of-use (U-1287)US 85636083.6y
Apr 29, 2030method-of-use (U-1287)US 85636083.6y
Apr 29, 2030method-of-use (U-2691)US 86175933.6y
Apr 29, 2030method-of-use (U-2691)US 86175933.6y
Apr 29, 2030method-of-use (U-1287)US 86175943.6y
Apr 29, 2030method-of-use (U-1287)US 86175943.6y
Apr 29, 2030method-of-use (U-2689)US 86181663.6y
Apr 29, 2030method-of-use (U-2692)US 86234063.6y
Apr 29, 2030method-of-use (U-1478)US 86234063.6y
Apr 29, 2030method-of-use (U-2693)US 86420773.6y
Apr 29, 2030method-of-use (U-2693)US 86420773.6y
Apr 29, 2030method-of-use (U-2689)US 86918713.6y
Apr 29, 2030method-of-use (U-2689)US 86918713.6y
Apr 29, 2030method-of-use (U-2691)US 87031853.6y
Apr 29, 2030method-of-use (U-2691)US 87031853.6y
Apr 29, 2030method-of-use (U-2689)US 87094753.6y
Apr 29, 2030method-of-use (U-2689)US 87094753.6y
Feb 9, 2030method-of-use (U-4105)US 121717383.4y
Feb 9, 2030method-of-use (U-4105)US 121717383.4y
Feb 9, 2030method-of-use (U-1287)US 83994463.4y
Feb 9, 2030method-of-use (U-1287)US 84153353.4y
Feb 9, 2030method-of-use (U-1287)US 84153353.4y
Feb 9, 2030method-of-use (U-1287)US 84263993.4y
Feb 9, 2030method-of-use (U-1287)US 84263993.4y
Feb 9, 2030method-of-use (U-1287)US 84315603.4y
Feb 9, 2030method-of-use (U-1287)US 85189293.4y
Feb 9, 2030method-of-use (U-1287)US 85189293.4y
Feb 9, 2030method-of-use (U-1287)US 85246983.4y
Feb 9, 2030method-of-use (U-1287)US 85246983.4y
Feb 9, 2030method-of-use (U-1287)US 85463723.4y
Feb 9, 2030method-of-use (U-1287)US 85463723.4y
Feb 9, 2030method-of-use (U-2695)US 86801443.4y
Feb 9, 2030method-of-use (U-2695)US 86801443.4y
Sep 25, 2027method-of-use (U-2706)US 9198892355d
Sep 25, 2027method-of-use (U-2706)US 9198892355d
May 31, 2027method-of-use (U-2707)US 9700537238d
May 31, 2027method-of-use (U-2707)US 9700537238d

News(10)

No ‘Sunday scaries’: Claire Mazumdar on building Bicara—and knowing when to hand over the reins
Strange and bittersweet. That’s how Claire Mazumdar describes her plan to step down from the top spot at Bicara, a biotech she helped form, and head out on parental leave before transitioning into…
biospace · 4d ago
Roche cuts muscle-sparing obesity drug after mid-stage disappointment
Roche’s anti-myostatin therapy emugrobart is unlikely to elicit meaningful weight loss, according to an interim mid-stage analysis, prompting the pharma to return the asset rights to its subsidiary…
biospace · 5d ago
Kodiak skyrockets on positive study data for 2 eye drugs
The Phase 3 findings suggested Kodiak might have multiple threats to Regeneron’s Eylea and added more than $3 billion to the company’s market value.
biopharma_dive · 6d ago
Tolerance continues thymus-focused deals with $560M pact for Tanabe's clinical-stage IL-33 drug
After vaulting into the clinic by licensing a fusion protein last month, Tolerance Bio has continued to strengthen its thymus-focused pipeline by picking up an anti-IL-33 drug from Tanabe Pharma.
fiercebiotech · 6d ago
Eli Lilly’s weekly insulin shot cleared by FDA, setting up another front in Novo rivalry
The weekly insulin Onswik will now be available to U.S. patients after initial approvals in Europe, Mexico and Japan.
biospace · 10d ago
Biohaven could get up to $795M in epilepsy alliance with SK Bio
At the center of Biohaven’s agreement with SK Biopharmaceutical is the ion channel platform and the lead epilepsy candidate opakalim, for which Phase 2/3 data are expected later this year.
biospace · 1mo ago
Spruce’s successful FDA talks plant seeds for Q4 filing of ultra-rare disease drug
Spruce Biosciences has taken another step toward filing for FDA approval of its ultra-rare disease drug candidate, ticking off some of the manufacturing tasks needed to submit the long-awaited appl…
fiercebiotech · 1mo ago
Tolerance Bio jumps into phase 2 with $260M deal for thymus-targeting fusion protein
Tolerance Bio has vaulted into the clinic by agreeing to pay NeoImmuneTech up to $260 million for rights to a fusion protein in certain thymus-related indications in the Americas and Europe.
fiercebiotech · 1mo ago
Chutes & Ladders—Former Legend CEO lands at K2
Just weeks after Legend Biotech announced the departure of its CEO, Ying Huang, K2 Therapeutics has announced that Wang will now lead the startup, which was founded in 2024 with a $50 million seed…
fiercebiotech · 1mo ago
GSK unveils 3-year cost-saving plan to fund late-stage R&D, move research HQ to AZ's backyard
GSK has unveiled an ambitious three-year plan to divert resources to its late-stage R&D programs and shift its research headquarters—but CEO Luke Miels is being tight-lipped about the extent of any…
fiercebiotech · 2mo ago

view all news mentions →

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 51m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

News(10)

No ‘Sunday scaries’: Claire Mazumdar on building Bicara—and knowing when to hand over the reins

Strange and bittersweet. That’s how Claire Mazumdar describes her plan to step down from the top spot at Bicara, a biotech she helped form, and head out on parental leave before transitioning into…

biospace · 4d ago

Roche cuts muscle-sparing obesity drug after mid-stage disappointment

Roche’s anti-myostatin therapy emugrobart is unlikely to elicit meaningful weight loss, according to an interim mid-stage analysis, prompting the pharma to return the asset rights to its subsidiary…

biospace · 5d ago

Kodiak skyrockets on positive study data for 2 eye drugs

The Phase 3 findings suggested Kodiak might have multiple threats to Regeneron’s Eylea and added more than $3 billion to the company’s market value.

biopharma_dive · 6d ago

Tolerance continues thymus-focused deals with $560M pact for Tanabe's clinical-stage IL-33 drug

After vaulting into the clinic by licensing a fusion protein last month, Tolerance Bio has continued to strengthen its thymus-focused pipeline by picking up an anti-IL-33 drug from Tanabe Pharma.

fiercebiotech · 6d ago

Eli Lilly’s weekly insulin shot cleared by FDA, setting up another front in Novo rivalry

The weekly insulin Onswik will now be available to U.S. patients after initial approvals in Europe, Mexico and Japan.

biospace · 10d ago

Biohaven could get up to $795M in epilepsy alliance with SK Bio

At the center of Biohaven’s agreement with SK Biopharmaceutical is the ion channel platform and the lead epilepsy candidate opakalim, for which Phase 2/3 data are expected later this year.

biospace · 1mo ago

Spruce’s successful FDA talks plant seeds for Q4 filing of ultra-rare disease drug

Spruce Biosciences has taken another step toward filing for FDA approval of its ultra-rare disease drug candidate, ticking off some of the manufacturing tasks needed to submit the long-awaited appl…

fiercebiotech · 1mo ago

Tolerance Bio jumps into phase 2 with $260M deal for thymus-targeting fusion protein

Tolerance Bio has vaulted into the clinic by agreeing to pay NeoImmuneTech up to $260 million for rights to a fusion protein in certain thymus-related indications in the Americas and Europe.

fiercebiotech · 1mo ago

Chutes & Ladders—Former Legend CEO lands at K2

Just weeks after Legend Biotech announced the departure of its CEO, Ying Huang, K2 Therapeutics has announced that Wang will now lead the startup, which was founded in 2024 with a $50 million seed…

fiercebiotech · 1mo ago

GSK unveils 3-year cost-saving plan to fund late-stage R&D, move research HQ to AZ's backyard

GSK has unveiled an ambitious three-year plan to divert resources to its late-stage R&D programs and shift its research headquarters—but CEO Luke Miels is being tight-lipped about the extent of any…

fiercebiotech · 2mo ago

view all news mentions →

icosapent ethyl

🐶 often sniffed alongside

all catalysts(0)

Trials studying icosapent ethyl

Patent cliff

patents (122)

News(10)

Report a data issue

comments(0)

icosapent ethyl

🐶 often sniffed alongside

all catalysts(0)

Trials studying icosapent ethyl

Patent cliff

patents (122)

News(10)

Report a data issue

comments(0)